3-(5-chloro-2-phenoxyphenyl)-1-methylpyrrolidine-2,4-dione

We are 3-(5-chloro-2-phenoxyphenyl)-1-methylpyrrolidine-2,4-dione CAS:1162120-35-5 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:3-(5-chloro-2-phenoxyphenyl)-1-methylpyrrolidine-2,4-dione
CAS.NO:1162120-35-5
Synonyms:3-(5-chloro-2-phenoxyphenyl)-1-methylpyrrolidine-2,4-dione
 
Physical and Chemical Properties:
Molecular Formula C17H14ClNO3
Molecular Weight 315.75100
 
Specification:
Appearance:Light yellow to yellow powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Asenapine(CAS:65576-45-6).

3-(5-chloro-2-phenoxyphenyl)-1-methylpyrrolidine-2,4-dione


Related News: Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova, added “The rigosertib Pre-approval Access Program is a key strategic initiative for Onconova.157329-89-0 It is estimated that the size of China’s CMO market has reached about USD 5 billion. With the implementation and further implementation of the MAH system (the core is to separate drug marketing authorization from drug production authorization) in China, it is expected to promote the outbreak of the domestic drug CMO industry. It will grow at a rate of 20% to 30%, of which patented APIs occupy a larger proportion.Tetrabenzyl Pyrophosphate CAS:990-91-0 It is estimated that the size of China’s CMO market has reached about USD 5 billion. With the implementation and further implementation of the MAH system (the core is to separate drug marketing authorization from drug production authorization) in China, it is expected to promote the outbreak of the domestic drug CMO industry. It will grow at a rate of 20% to 30%, of which patented APIs occupy a larger proportion.4-(trifluoromethoxy)phenyl chlorothioformate CAS:2251-66-3 In recent years, there has been a relatively concentrated concentration of intermediate companies listed on the capital market. Most of the fund-raising projects are aimed at breaking through the bottleneck of production capacity to meet growing demand, and the entire industry has shown a vigorous development momentum.Bristol-Myers Squibb (BMS) recently acquired Celgene, for example, which had the highest proportional R&D spend.

Related Products
Product Name
1-Butyl-3-methylimidazolium bromide View Details
3-(2-BROMO-4,5-DIMETHOXYPHENYL)PROPANENITRILE View Details
beta-Diphosphopyridine nucleotide View Details
4-Methoxy-2-Methyldiphenylamine manufacturer HC Yellow 7 manufacturer 1,3-Dichloro-5-fluorobenzene manufacturer Bis(Tetramethylene)Fluoroformamidinium Hexafluorophosphate manufacturer 5′-Chloro-3-hydroxy-2′,4′-dimethoxy-2-naphthanilide manufacturer